Sphingomyelinase inhibition suggests a possible new strategy for the treatment of inflammatory bowel disease

Current Drug Therapy

Volumn 3, Issue 3, 2008, Pages 218-225

  Soeda, Shinji ^a   Sakata, Akira ^a,e   Ochiai, Takashi ^a   Yasuda, Kazuya ^a   Kuramoto, Yukako ^a   Shimeno, Hiroshi ^a   Toda, Akihisa ^b   Eyanagi, Reiko ^b   Hikishima, Sadao ^c   Yokomastu, Tsutomu ^c   Shibuya, Shiroshi ^d  

^a FUKUOKA UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d TEIKYO HEISEI UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Ceramide; Inflammatory bowel disease; Inflammatory cytokines; Macrophages; Nuclear factor B; Sphingomyelinase inhibitor

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTACYSTIN; LIPOPOLYSACCHARIDE; MESALAZINE; PHOSPHODIESTERASE INHIBITOR; SALAZOSULFAPYRIDINE; SCYPHOSTATIN; SPHINGOMYELIN 7; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; CELL VIABILITY; COLON CROHN DISEASE; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG DESIGN; DRUG RESPONSE; DRUG STRUCTURE; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; INTESTINE EPITHELIUM CELL; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 54849404494     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488508785747853     Document Type: Review

References (66)

1. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79: 319-26.
2. Dentener MA, Bazil V, Von Asmuth EJ. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-α, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993; 150: 2885-91.
3. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol 1997; 60: 8-26.
4. Baeuerie PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20.
5. Baeuerie PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 1998; 8: R19-R22.
6. Eckmann L, Kagnoff MF, Fierer J. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun 1993; 61: 4569-74.
7. Schuerer-Maly CC, Eckmann L, Kagnoff MF, Falco MT, Maly FE. Colonic epithelial cell lines as a source of inlerleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology 1994; 81: 85-91.
8. Jung HC, Eckmann L, Yang SK, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995; 95: 55-65.
9. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-9.
10. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22: 382-9.
11. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-69.
12. MacKichan ML, DeFranco AL. Role of ceramide in lipopolysacchairde (LPS)-induced signaling: LPS increases ceramide rather than acting as a structural homolog. J Biol Chem 1999; 274: 1767-75.
13. Medvedev AE, Blanco JCG, Qureshi N, Vogel SN. Limited role of ceramide in lipopolysaccharide-mediated mitogen-activated protein kinase activation, transcription factor induction, and cytokine release. J Biol Chem 1999; 274: 9342-50.
14. Spiegel S, Foster D, Kolesnick R. Signal transduction through lipid second messengers. Curr Opin Cell Biol 1996; 8: 159-67.
15. Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 2004; 82: 27-44.
16. Yokomatsu T, Takechi H, Akiyama T, et al. Synthesis and evaluation of a difluoromethylene analogue of sphingomyelin as an inhibitor of sphingomyelinase. Bioorg Med Chem Lett 2001; 11: 1277-80.
17. Yokomatsu T, Murano T, Akiyama T, et al. Synthesis of non-competitive inhibitors of sphingomyelinases with significant activity. Bioorg Med Chem Lett 2003; 13: 229-36.
18. Sakata A, Ochiai T, Shimeno H, et al. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 2007; 122: 54-64.
19. Sakata A, Yasuda K, Ochiai T, et al. Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis in mice. Cell Immunol 2007; 245: 24-31.
20. Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1-signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274: 7611-4.
21. Levade T, Jaffrezou JP. Signalling sphingomyelinases: which, where, how and why? Biochim Biophys Acta 1999; 1438: 1-17.
22. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 2001; 31: 717-28.
23. Goni FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett 2002; 531: 38-46.
24. Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 2004; 82: 27-44.
25. Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J 2001; 77: 436-40.
26. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
27. Schulzke JD, Bojarski C, Zeissig S, Heller F, Gitter AH, Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann NY Acad Sci 2006; 1072: 288-99.
28. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999; 11: 648-56.
29. Mahida YR, Patel S, Gionchetti P, Vaux D, Jewell DP. Macrophage subpopulations in lamina propria of normal and inflamed colon and terminal ileum. Gut 1989; 30: 826-34.
30. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163-74.
31. 2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol 1997; 53: 1901-7.
32. Gomez-Munoz A, O'Brien L, Salh B, Steinbrecher UP. 5-Aminosalicylate stimulates phospholipase D activity in macrophages: Biochim Biophys Acta 2001; 110-18.
33. Aoki K. A study of endotoxaemia in ulcerative colitis and Crohn's disease. I. Clinical study. Acta Med Okayama 1978; 32: 147-58.
34. Wellmann W, Fink PC, Benner F, Schmidt FW. Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut 1986; 27: 814-20.
35. Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897-901.
36. + population of monocytes in inflammatory bowel disease mucosa: implications for pathogenesis. Clin Exp Immunol 1995; 100: 291-7.
37. Zareie M, McKay DM, Kovarik GG, Perdue MH. Monocyte/macrophagers evoke epithelial dysfunction: indirect role of tumor necrosis factor-α. Am J Physiol 1998; 275: C932-9.
38. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8.
39. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-608.
40. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997; 349: 521-4.
41. Sandborn WJ, Feagan BG, Hanauer SB, et al. CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120: 1330-8.
42. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932-7.
43. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994; 78: 1005-15.
44. Cifone MG, Roncaioli P, De Maria R, et al. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J 1995; 14: 5859-68.
45. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-92.
46. Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH. Monocyte/ macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol 2001; 158: 1101-9.
47. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
48. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
49. Shirakabe K, Yamaguchi K, Shibuya H, et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 1997; 272: 8141-4.
50. Strater J, Wellisch I, Riedl S, et al. CD95 (APO-1/Fas)-mediated apoptosis and barrier repair in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997; 113: 160-7.
51. Mukaida N, Okamoto S, Ishikawa Y, Matsushima K. Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 1994; 56: 554-8.
52. Oliveira IC, Mukaida N, Matsushima K, Vilcek J. Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-κB site. Mol Cell Biol 1994; 14: 5300-8.
53. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Ann Rev Immunol 1994; 12: 141-79.
54. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF 6 is a signal transducer for interleukin-1. Nature 1996; 383: 443-6.
55. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF 2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996; 271: 19935-42.
56. Jobin C, Sartor RB. The I kappaB/NF-kappaB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-C462.
57. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Ann Rev Immunol 2000; 18: 621-63.
58. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998; 94: 557-72.
59. Nikolaus S, Folsch U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000; 47: 71-82.
60. Herfarth H, Brand K, Rath HC, Rogler G, Schölmerich J, Falk W. Nuclear factor-κB activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 2000; 120: 59-65.
61. Ortega-Cava CF, Ishihara S, Rumi MA, et al. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003; 170: 3977-85.
62. Ohkawara T, Takeda H, Nishihira J, et al. Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin Exp Immunol 2005; 141: 412-21.
63. Nara F, Tanaka M, Masuda-Inoue S, et al. Biological activities of scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima. J Antibiot 1999; 52: 531-5.
64. Soeda S, Tsuji Y, Ochiai T, et al. Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress. Neurochem Int 2004; 45: 619-26.
65. Yu ZF, Nikolva-Karakashian M, Zhou D, Cheng G, Schuchman EH, Mattson MP. Pivotal role for acid sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci 2000; 15: 85-97.
66. Bernardo K, Krut O, Wiegmann K, et al. Purification and characterization of a magnesium-dependent neutral sphingomyelinase from bovine brain. J Biol Chem 2000; 275: 7641-7.